^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:RVU120 (CDK19 inhibitor, CDK8 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2021
    Title:

    CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

    Published date:
    11/04/2021
    Excerpt:
    In Cohort #4 (75 mg), a R/R AML patient with DNMT3A mutation achieved a Complete Remission (CR) being in disease progression under venetoclax/decitabine treatment….RVU120 shows preliminary signs of efficacy in AML and HR-MDS with a tolerable safety profile, including a CR and an ER in patients previously treated with venetoclax combination therapy.
    DOI:
    10.1182/blood-2021-151030